DUBLIN--(BUSINESS WIRE)--The "Cell Line Development Services Global Market" report has been added to ResearchAndMarkets.com's offering.
According to the report, the Cell Line Development services market is expected to grow at a high double digit CAGR to reach $1,519.5 million by 2027.
Increasing demand for biologics and biosimilars, growing incidence rate of oncology and immunological disorder and growth in research activities related to the diseases are driving the market.
Technological improvements in development, manufacturing, screening technologies and assays are giving immense growth opportunity for the market.
However, complexities in development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market.
Furthermore, stringent and complex regulations and high cost and technical requirement to adhere with accreditations such as GMP are posing threat to the industry.
Some of the major companies in the cell line development market include JSR Life Science (Selexis), Lonza (Switzerland), Boehringer Ingelheim (Germany), Catalent (U.S.), Samsung Biologics (South Korea), Fujifilm Diosynth (Japan), Patheon (Thermo Fisher Scientific) (U.S.), AGC Biologics (U.S.), Merck KGaA (Germany), Rentschler Biotech (Germany), Genscript Biotech (China), Horizon Discovery (U.K.), Sartoris AG (France), Wuxi Apptec (China), and Eurofins (Luxembourg).
Some of the other players are Syngene (India), Evotec (Germany), Lake Pharma (U.S.), TCG Lifescience (India), Cobra Biologics (U.K.), Abzena (U.K.), JHL Biotech (Taiwan), Charles River Laboratories (U.S.), Mabplex (U.S.), Trenzyme (Germany), Atum (U.S.), ATCC (U.S.).
Topics Covered
1 Executive Summary
2 Market Dynamics
3 Cell Line Development
4 Host Cell Lines
5 Cell Line Development Services, By Cell Type
6 Cell Line Development Services, By Application
7 Key Developments
8 Market Share Analysis
9 Company Profiles
- AGC Biologics
- Boehringer Ingelheim
- Catalent Inc.
- Eurofins Scientific Group
- Genscript Biotech Corporation
- Horizon Discovery Group PLC
- JHL Biotech Inc.
- JSR Life Sciences (Selexis SA)
- Lonza Group
- Merck KGaA
- Patheon (Thermo Fisher Scientific)
- Rentschler Biopharma SE
- Samsung Biologics
- Sartorius AG
- Wuxi Biologics (Wuxi Apptec)
For more information about this report visit https://www.researchandmarkets.com/research/fv7487/1_5_billion?w=4
